Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being... see more

Recent & Breaking News (NDAQ:UNCY)

Unicycive to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 6, 2022

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

GlobeNewswire June 2, 2022

Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.

Accesswire May 24, 2022

Unicycive Announces First Quarter Financial Results and Provides Business Update

GlobeNewswire May 12, 2022

Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.

Business Wire April 14, 2022

Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases

GlobeNewswire April 14, 2022

Unicycive Announces Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 31, 2022

Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022

GlobeNewswire March 23, 2022

Unicycive to Present at Upcoming March Investor Conferences

PR Newswire March 3, 2022

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting

PR Newswire February 2, 2022

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

PR Newswire January 10, 2022

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway

PR Newswire November 29, 2021

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results

PR Newswire November 11, 2021